Multidrug resistance

While tuberculosis (TB) has become relatively rare in Germany and other industrialised nations, around ten million people contract the bacterial infection every year, especially in resource-poorer

A recent clinical study shows that ganfeborole could be a promising candidate for the safe and effective treatment of pulmonary tuberculosis. Using microbiological testing and innovative imaging

Epstein-Barr Virus (EBV) is widespread and very contagious: according to the World Health Association, more than 90 percent of the global population are infected with this virus throughout their lives

BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug

Tuberculosis is currently the infectious disease that causes the most deaths worldwide. Of particular concern is the increasing emergence of multidrug-resistant tuberculosis bacteria, particularly in

Bacteria that are resistant to broad-spectrum antibiotics from the carbapenem group are increasingly posing major problems for healthcare systems worldwide. They can cause serious infections and

From 18 to 24 November, the “World AMR Awareness Week” (WAAW), a global campaign proclaimed by WHO, aims to draw attention to the near-pandemic rise in infections caused by resistant microbial

With one of the highest tuberculosis (TB) incidences (368 cases/100,000 population) in the African region, Mozambique is particularly affected by the TB epidemic. Drug-resistant TB is also a major

Today, UNITE4TB, an international public-private partnership striving to fast-track the development of innovative tuberculosis (TB) treatments, announced the start of its phase-IIb/c-clinical trial

Researchers from the German Center for Infection Research (DZIF) at the University of Cologne have conducted a study on the carbapenem-resistant bacterium Acinetobacter baumannii. The pathogen was